Compounding Quality Matters: What Providers Should Look for in a Pharmacy Partner

A patient needs a strength that is unavailable commercially. Another cannot swallow the prescribed tablet. For a third, an inactive ingredient makes an otherwise appropriate medication difficult to tolerate.

Compounding may help address these needs. Choosing the right pharmacy deserves careful attention.

Providers need to understand how a potential partner evaluates prescriptions, prepares medications, and responds when questions arise. Credentials offer a starting point; specific answers about daily practices reveal more. The most useful evaluation connects those practices to the preparations your patients will actually receive.

Choosing a Compounding Pharmacy: Start With the Patient’s Needs

First, establish the reason for compounding. Confirm whether a suitable FDA-approved product can meet the patient’s needs, then discuss any remaining strength, formulation, or ingredient barriers with the pharmacist.

Ask about experience with the proposed preparation.

A pharmacy that routinely prepares capsules and creams may have different capabilities from one preparing sterile injections or ophthalmic medications. Changing a dosage form or route also raises questions about stability, absorption, and dosing. A helpful partner explains what is feasible, identifies limitations, and requests clarification before proceeding.

Compounding Pharmacy Licensing: Understand the 503A Model

A 503A pharmacy generally prepares patient-specific medications pursuant to valid prescriptions, subject to the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act and other applicable requirements.

Verify active licensure through the relevant state board. For out-of-state patients, confirm that the pharmacy is authorized to dispense into their state.

State boards generally provide day-to-day oversight of pharmacies that are not registered outsourcing facilities; FDA also conducts surveillance and for-cause inspections. Review publicly available disciplinary, inspection, and recall information, and ask about relevant findings and corrective actions.

The 503A model differs from a registered 503B outsourcing facility, which is subject to current good manufacturing practice requirements. Neither designation makes compounded medications FDA-approved.

PCAB Accreditation: Verify the Scope

PCAB accreditation, offered through the Accreditation Commission for Health Care, assesses compounding practices against accreditation standards. It is separate from licensure.

Ask for current documentation. Does it cover sterile compounding, nonsterile compounding, or both? Does it apply to the location preparing your prescriptions?

Pharmacy Solutions identifies accreditation in both sterile and nonsterile compounding on its primary care provider page. Providers can discuss current documentation and preparation capabilities with the team.

Accreditation is a useful part of the evaluation. It does not confer FDA approval or guarantee a clinical outcome.

USP Compounding Standards: Match Them to the Preparation

United States Pharmacopeia, or USP, develops standards for different aspects of compounding:

• USP <795> addresses nonsterile preparations, including many capsules, creams, and oral liquids.
• USP <797> addresses sterile compounding, including personnel, facilities, and environmental monitoring.
• USP <800> addresses hazardous-drug handling to minimize exposure to personnel, patients, and the environment.

More than one chapter may apply. Hazardous-drug handling, for example, can be relevant to either sterile or nonsterile work.

Ask how the pharmacy addresses the standards relevant to your prescription. For sterile preparations, that discussion should include staff qualification and cleanroom controls. For hazardous drugs, ask about handling and containment. Applicable legal requirements determine how standards are enforced.

Compounding Pharmacy Quality Assurance: Look Behind the Claim

“High quality” needs an explanation.

Ask how the pharmacy qualifies suppliers, checks incoming ingredients, and records lot information. For bulk drug substances used under section 503A, FDA describes requirements including a valid certificate of analysis, manufacture by an FDA-registered establishment, and applicable substance-eligibility conditions. Registration does not establish FDA approval.

Next, clarify the testing program. Potency, sterility, endotoxin, and stability assessments answer different questions; the pharmacy should explain which tests apply, how sampling works, and what the results demonstrate.

Do not assume that every dispensed unit receives every laboratory test.

Documentation matters, too. Ask how the pharmacy traces materials used in a preparation and investigates complaints or suspected defects. The answers should make clear who reviews a concern and how affected providers and patients are notified when necessary.

Beyond-Use Dates: Review Storage and Patient Instructions

A beyond-use date, or BUD, identifies when a compounded preparation should no longer be used. It differs from a manufacturer’s expiration date.

Ask how the assigned BUD is supported for the formulation, container, and storage conditions. Then review the instructions patients receive: the dose, route, storage requirements, and preparation-specific directions, such as shaking a suspension.

Delivery belongs in this conversation. Confirm how temperature-sensitive preparations are handled and whom patients should contact if a shipment arrives with a concern.

Prescriber–Pharmacist Collaboration: Expect Clear Communication

Can you reach a pharmacist when a prescription needs clarification? Establish that process before the first order.

Agree on active ingredients, concentration, dosage form, route, and directions. Clear units are especially important when patients must measure a liquid or injectable dose. A concentration change between refills may also require a different volume and updated instructions.

Ask how proposed changes are communicated and authorized, and confirm realistic turnaround expectations for your practice.

Pharmacy Solutions offers direct pharmacist access for clinical compounding questions. Providers can use that access to discuss patient-specific needs and feasibility before prescribing.

The relationship should remain responsive as those needs change. Revisit capabilities and communication expectations when your practice begins prescribing a new type of preparation.

Talk With Pharmacy Solutions About Your Practice’s Compounding Needs

Evaluate a potential pharmacy partnership through a direct conversation about quality practices and patient-specific requirements. Contact Pharmacy Solutions to discuss accreditation, preparation capabilities, and how its pharmacists can collaborate with your practice.

Frequently Asked Questions

What should providers look for in a compounding pharmacy?

Providers should verify active licensing, assess relevant accreditation and capabilities, and ask about ingredient sourcing, documentation, testing, beyond-use dates, and pharmacist communication. The evaluation should match the specific preparations patients need.

Does PCAB accreditation make compounded medications FDA-approved?

No. PCAB accreditation evaluates pharmacy practices against accreditation standards. It does not confer FDA approval on compounded medications, which are not reviewed by FDA for safety, effectiveness, or quality before marketing.

What is the difference between sterile and nonsterile compounding?

Sterile compounding prepares medications that must meet sterility requirements, such as certain injectable and ophthalmic preparations. Nonsterile compounding includes preparations such as many capsules, creams, and oral liquids. Their processes and applicable standards differ.

Does every compounded medication receive the same testing?

No. Testing depends on the preparation, applicable standards, and quality program. Providers should ask what is tested, how sampling is performed, and what the results demonstrate.

Is a beyond-use date the same as an expiration date?

No. A beyond-use date specifies when a compounded preparation should no longer be used. It is assigned using applicable standards and formulation-specific considerations. It is distinct from a manufacturer’s expiration date.

This article is intended for healthcare professional education and does not replace current regulatory requirements, prescribing information, or individualized clinical judgment. Compounded medications are not FDA-approved.